Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-randomized, Phase II, Open-label Study for Efficacy and Safety of Everolimus in Relapsed or Refractory Hemangioendothelioma and Other ISSVA Group I or II Vascular Malformation and Neoplasms

NCT07477548 is registered in ClinicalTrials.gov with Yonsei University as lead sponsor.

NCT NCT07477548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07477548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-randomized, Phase II, Open-label Study for Efficacy and Safety of Everolimus in Relapsed or Refractory Hemangioendothelioma and Other ISSVA Group I or II Vascular Malformation and Neoplasms
Lead sponsor
Yonsei University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 1, 2026
Completion date
November 30, 2030
Enrollment
67 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

arteriovenous malformations, hemangioendothelioma, hemangioma, lymphangioma, nevus, port-wine, vascular malformations, venous malformation